IL2 and cancer: The combination therapy of a stimulator of interferon gene (STING) agonist with extended half-life IL-2 and anti-PD-1 (CIP therapy) considerably enhances the cancer response in TNBC models by upregulating the expression of IFNAR-1 and CD25 on lung NK cells 169.